Therapeutic potential of tolerance-based peptide vaccines in autoimmune diseases

Int Immunopharmacol. 2023 Mar:116:109740. doi: 10.1016/j.intimp.2023.109740. Epub 2023 Jan 23.

Abstract

Autoimmune diseases are caused by the dysfunction of the body's immune regulatory system, which leads to the recognition of self-antigens and the destruction of self-tissues and is mediated by immune cells such as T and B cells, and affects 5-10% of the population worldwide. Current treatments such as non-steroidal anti-inflammatory drugs and glucocorticoids can only relieve symptoms of the disease and are accompanied by serious side effects that affect patient quality of life. The recent rise in antigen-specific therapies, especially vaccines carrying autoantigenic peptides, promises to change this disadvantage, where research has increased dramatically in the last decade. This therapy established specific immune tolerance by delivering peptide fragments containing disease-specific self-antigen epitopes to suppress excessive immune responses, thereby exerting a therapeutic effect, with high safety and specificity. This article presents the latest progress on the treatment of autoimmune diseases with autoantigen peptide vaccines. It includes the construction of peptide vaccine delivery system, the mechanism of inducing immune tolerance and its application.

Keywords: Antigen-specific therapies; Autoimmune diseases; Immune tolerance; Peptide vaccines.

Publication types

  • Review

MeSH terms

  • Autoantigens
  • Autoimmune Diseases*
  • Humans
  • Immune Tolerance
  • Quality of Life
  • Vaccines* / therapeutic use
  • Vaccines, Subunit / therapeutic use

Substances

  • Vaccines
  • Autoantigens
  • Vaccines, Subunit